Extracellular vesicle bioactivity and potential for clinical development are determined by mesenchymal stromal cell clonal subtype.

ABSTRACT:

Background

Mesenchymal stromal cells (MSCs) have been used in numerous clinical trials but very few reach phase 3 or market authorisation. Progress is often hampered by the use of non-clonal, heterogeneous and uncharacterised MSC cultures and lack of mechanistic understanding. There is limited evidence of MSC engraftment in vivo and disease resolution may be the result of the paracrine effects of the MSC secretome, rather than the cells per se. Extracellular vesicles (EVs) are key components of the MSC secretome and there is growing interest in the use of EVs as cell-free therapies. However, like MSCs, heterogeneity can exist within any therapeutic EV pool. Here we used immortalised clonal MSC lines, termed Y201 and Y202, to examine how MSC phenotype influences EV character and fun

SUBMITTER: Ioannou S 

PROVIDER: S-EPMC12532472 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature